Baxter International Inc. (BAX Quick QuoteBAX - Free Report) is a global medical products and services company. The company’s Hospital Products business manufactures products used in the delivery of fluids and drugs to patients. Renal portfolio is mainly for patients with kidney failure/disease and their healthcare providers.

Currently, Baxter International has a Zacks Rank #4 (Sell) but that could change following its second quarter 2016 earnings report which has just released. We have highlighted some of the key details from the just-released announcement below:
 
Earnings: The Zacks Consensus Estimate remained steady at 39 cents per share over the last 60 days. Baxter’s adjusted earnings of 46 cents per share beat this estimate by almost 18% and increased a massive 142% from the year-ago quarter.
 
Revenues: Baxter posted sales of $2.59 billion, beating the Zacks Consensus Estimate for revenues of $2.50 billion. At constant currency (cc), revenues increased 6% on a year-over-year basis.
 
Key Stats: Hospital products sales increased 7% at cc, while renal products inched up 2% from the year-ago quarter.
 

Major Factors:  Hospital Products sales were driven by solid demand for SIGMA SPECTRUM infusion pump and favorable pricing for IV solutions. Renal products sales were driven by increasing demand for replacement therapies along with strong sales of peritoneal dialysis products.

Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
 
Check back later for our full write up on this Baxter International report later!

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>